Chloroquine: Modes Of Action Of An Undervalued Drug

For more than two decades, chloroquine (CQ) was largely and deliberately used as first choice drug for malaria treatment. However, worldwide increasing cases of resistant strains of Plasmodium have hampered its use. Nevertheless, CQ has recently been tested as adjunct therapy in several inflammatory situations, such as rheumatoid arthritis and transplantation procedures, presenting intriguing and promising results. In this review, we discuss recent findings and CQ mechanisms of action vis-à-vis its use as a broad adjunct therapy. © 2013 Elsevier B.V.1531/Fev5057(2011) World Malaria Report 2011, , World Health Organization, Geneva World Health OrganizationA research agenda for malaria eradication: drugs (2011) PLoS Medicine, 8, pp. e1000402. , malERA Consultative Group on DrugsPlowe, C.V., The evolution of drug-resistant malaria (2009) Transactions of the Royal Society of Tropical Medicine and Hygiene, 103 (SUPPL. 1), pp. S11-S14Summers, R.L., Nash, M.N., Martin, R.E., Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics (2012) Cellular and Molecular Life Sciences, 69, pp. 1967-1995A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study (1995) American Journal of Medicine, 98, pp. 156-168Bezerra, E.L., Vilar, M.J., da Trindade Neto, P.B., Sato, E.L., Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus (2005) Arthritis and Rheumatism, 52, pp. 3073-3078Ben-Zvi, I., Kivity, S., Langevitz, P., Shoenfeld, Y., Hydroxychloroquine: from malaria to autoimmunity (2012) Clinical Reviews in Allergy & Immunology, 42, pp. 145-153Homewood, C.A., Warhurst, D.C., Peters, W., Baggaley, V.C., Lysosomes, pH and the anti-malarial action of chloroquine (1972) Nature, 235, pp. 50-52Chiang, G., Sassaroli, M., Louie, M., Chen, H., Stecher, V.J., Sperber, K., Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine (1996) Clinical Therapeutics, 18, pp. 1080-1092Sperber, K., Chiang, G., Chen, H., Ross, W., Chusid, E., Gonchar, M., Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1 (1997) Clinical Therapeutics, 19, pp. 913-923Bernstein, H.N., Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy (1983) American Journal of Medicine, 75, pp. 25-34Karres, I., Chloroquine inhibits proinflammatory cytokine release into human whole blood (1998) American Journal of Physiology, 274, pp. R1058-R1064Ertel, W., Morrison, M.H., Ayala, A., Chaudry, I.H., Chloroquine attenuates hemorrhagic shock-induced immunosuppression and decreases susceptibility to sepsis (1992) Archives of Surgery, 127, pp. 70-75. , [discussion 75-76]Loehberg, C.R., Strissel, P.L., Dittrich, R., Strick, R., Dittmer, J., Dittmer, A., Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001 (2012) Biochemical Pharmacology, 83, pp. 480-488Sperber, K., Kalb, T.H., Stecher, V.J., Banerjee, R., Mayer, L., Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes (1993) AIDS Research and Human Retroviruses, 9, pp. 91-98Yoshimura, A., Kuroda, K., Kawasaki, K., Yamashina, S., Maeda, T., Ohnishi, S., Infectious cell entry mechanism of influenza virus (1982) Journal of Virology, 43, pp. 284-293Shibata, M., Aoki, H., Tsurumi, T., Sugiura, Y., Nishiyama, Y., Suzuki, S., Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine (1983) Journal of General Virology, 64, pp. 1149-1156Ooi, E.E., Chew, J.S., Loh, J.P., Chua, R.C., In vitro inhibition of human influenza A virus replication by chloroquine (2006) Virology Journal, 3, p. 39Di Trani, L., Savarino, A., Campitelli, L., Norelli, S., Puzelli, S., D'Ostilio, D., Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses (2007) Virology Journal, 4, p. 39Misinzo, G., Delputte, P.L., Nauwynck, H.J., Inhibition of endosome-lysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells (2008) Journal of Virology, 82, pp. 1128-1135Savarino, A., A historical sketch of the discovery and development of HIV-1 integrase inhibitors (2006) Expert Opinion on Investigational Drugs, 15, pp. 1507-1522Bernstein, H.N., Chloroquine ocular toxicity (1967) Survey of Ophthalmology, 12, pp. 415-447Sperber, K., Louie, M., Kraus, T., Proner, J., Sapira, E., Lin, S., Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1 (1995) Clinical Therapeutics, 17, pp. 622-636Murray, S.M., Down, C.M., Boulware, D.R., Stauffer, W.M., Cavert, W.P., Schacker, T.W., Reduction of immune activation with chloroquine therapy during chronic HIV infection (2010) Journal of Virology, 84, pp. 12082-12086Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B., Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders (2011) Blood, 118, pp. 3263-3272Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., Cotte, L., Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients (2001) Blood, 98, pp. 906-912Martinson, J.A., Montoya, C.J., Usuga, X., Ronquillo, R., Landay, A.L., Desai, S.N., Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation (2010) Antimicrobial Agents and Chemotherapy, 54, pp. 871-881Jiang, M.C., Lin, J.K., Chen, S.S., Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine (1996) Biochemical and Biophysical Research Communications, 226, pp. 1-7Fredericksen, B.L., Wei, B.L., Yao, J., Luo, T., Garcia, J.V., Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus (2002) Journal of Virology, 76, pp. 11440-11446Canadian Consensus Conference on hydroxychloroquine (2000) Journal of Rheumatology, 27, pp. 2919-2921. , Canadian Rheumatology AssociationGladman, D.D., Urowitz, M.B., Senecal, J.L., Fortin, P.J., Petty, R.E., Esdaile, J.M., Aspects of use of antimalarials in systemic lupus erythematosus (1998) Journal of Rheumatology, 25, pp. 983-985Rahman, A., Isenberg, D.A., Systemic lupus erythematosus (2008) New England Journal of Medicine, 358, pp. 929-939Slater, A.F., Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum (1993) Pharmacology & Therapeutics, 57, pp. 203-235Tan, E.M., Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology (1989) Advances in Immunology, 44, pp. 93-151Casciola-Rosen, L.A., Anhalt, G., Rosen, A., Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes (1994) Journal of Experimental Medicine, 179, pp. 1317-1330A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group (1991) N Engl J Med, 324, pp. 150-154Fessler, B.J., Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual (2005) Arthritis and Rheumatism, 52, pp. 1473-1480Alarcon, G.S., Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINAL) (2007) Annals of the Rheumatic Diseases, 66, pp. 1168-1172Ruiz-Irastorza, G., Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus (2006) Lupus, 15, pp. 577-583Tam, L.S., Gladman, D.D., Hallett, D.C., Rahman, P., Urowitz, M.B., Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus (2000) Journal of Rheumatology, 27, pp. 2142-2145Levy, R.A., Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study (2001) Lupus, 10, pp. 401-404Lesiak, A., Narbutt, J., Kobos, J., Kordek, R., Sysa-Jedrzejowska, A., Norval, M., Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis (2009) Clinical and Experimental Dermatology, 34, pp. 570-575Kreuter, A., Gaifullina, R., Tigges, C., Kirschke, J., Altmeyer, P., Gambichler, T., Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking (2009) Archives of Dermatology, 145, pp. 244-248Coatney, G.R., Pitfalls in a discovery: the chronicle of chloroquine (1963) American Journal of Tropical Medicine and Hygiene, 12, pp. 121-128Ikeda, T., Kanazawa, N., Furukawa, F., Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study (2012) Journal of Dermatology, 39, pp. 531-535Kuhn, A., Ruland, V., Bonsmann, G., Cutaneous lupus erythematosus: update of therapeutic options. Part I (2011) Journal of the American Academy of Dermatology, 65, pp. e179-e193Momose, Y., Arai, S., Eto, H., Kishimoto, M., Okada, M., Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus (2013) Journal of Dermatology, 40, pp. 94-97Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis (1988) Arthritis and Rheumatism, 31, pp. 315-324Louzada-Junior, P., Freitas, M.V., Oliveira, R.D., Deghaide, N.H., Conde, R.A., Bertolo, M.B., A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrunillated peptide antibodies (2008) Brazilian Journal of Medical and Biological Research, 41, pp. 493-499Perricone, C., Ceccarelli, F., Valesini, G., An overview on the genetic of rheumatoid arthritis: a never-ending story (2011) Autoimmunity Reviews, 10, pp. 599-608Takayanagi, H., Inflammatory bone destruction and osteoimmunology (2005) Journal of Periodontal Research, 40, pp. 287-293Takayanagi, H., Oda, H., Yamamoto, S., Kawaguchi, H., Tanaka, S., Nishikawa, T., A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis (1997) Biochemical and Biophysical Research Communications, 240, pp. 279-286Yamada, H., Nakashima, Y., Okazaki, K., Mawatari, T., Fukushi, J.I., Kaibara, N., Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis (2008) Annals of the Rheumatic Diseases, 67, pp. 1299-1304Hashimoto, M., Hirota, K., Yoshitomi, H., Maeda, S., Teradaira, S., Akizuki, S., Complement drives Th17 cell differentiation and triggers autoimmune arthritis (2009) Journal of Experimental Medicine, 207, pp. 1135-1143Loeb, R.F., Clark, W.M., Coatney, G.R., Coggeshall, T., Dieuaide, F.R., Dochez, A.R., Activity of a new antimalarial agent, chloroquine (SN 7618) (1946) Journal of the American Medical Association, 130, p. 1069Korn, T., Bettelli, E., Oukka, M., Kuchroo, V.K., IL-17 and Th17 Cells (2009) Annual Review of Immunology, 27, pp. 485-517Felson, D.T., Anderson, J.J., Meenan, R.F., The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses (1990) Arthritis and Rheumatism, 33, pp. 1449-1461Scott, D.L., Dawes, P.T., Tunn, E., Fowler, P.D., Shadforth, M.F., Fisher, J., Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study (1989) British Journal of Rheumatology, 28, pp. 128-133McCarty, D.J., Carrera, G.F., Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine (1982) JAMA: Journal of the American Medical Association, 248, pp. 1718-1723Bunch, T.W., O'Duffy, J.D., Tompkins, R.B., O'Fallon, W.M., Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis (1984) Arthritis and Rheumatism, 27, pp. 267-276Gibson, T., Emery, P., Armstrong, R.D., Crisp, A.J., Combined, P.G.S., D-penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative study (1987) British Journal of Rheumatology, 26, pp. 279-284Thome, R., Moraes, A.S., Bombeiro, A.L., Farias, A.D., Francelin, C., da Costa, T.A., Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis (2013) PLoS ONE, 8, pp. e65913Schultz, K.R., Gilman, A.L., The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease (1997) Leukemia & Lymphoma, 24, pp. 201-210Schultz, K.R., Su, W.N., Hsiao, C.C., Doho, G., Jevon, G., Bader, S., Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production (2002) Biology of Blood and Marrow Transplantation, 8, pp. 648-655Gilman, A.L., Beams, F., Tefft, M., Mazumder, A., The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease (1996) Bone Marrow Transplantation, 17, pp. 1069-1075Harinasuta, T., Suntharasamai, P., Viravan, C., Chloroquine-resistant falciparum malaria in Thailand (1965) Lancet, 2, pp. 657-660Gilman, A.L., Chan, K.W., Mogul, A., Morris, C., Goldman, F.D., Boyer, M., Hydroxychloroquine for the treatment of chronic graft-versus-host disease (2000) Biology of Blood and Marrow Transplantation, 6, pp. 327-334Schultz, K.R., Bader, S., Paquet, J., Li, W., Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease (1995) Blood, 86, pp. 4344-4352Hobbs, H.E., Sorsby, A., Freedman, A., Retinopathy following chloroquine therapy (1959) Lancet, 2, pp. 478-480Madalena, B.V., Oshima, A., Serracarbassa, P.D., Amsler grid and visual field on screening for chloroquine retinopathy (2012) Arquivos brasileiros de oftalmologia, 75, pp. 170-173Levy, G.D., Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice (1997) Arthritis and Rheumatism, 40, pp. 1482-1486Marmor, M.F., Kellner, U., Lai, T.Y., Lyons, J.S., Meiler, W.F., Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2011) Ophthalmology, 118, pp. 415-422Marmor, M.F., Carr, R.E., Easterbrook, M., Farjo, A.A., Mieler, W.F., Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology (2002) Ophthalmology, 109, pp. 1377-1382Rossi, P., Fossaluzza, V., Gonano, L., Localized scleroderma evolving into systemic sclerosis (1985) Journal of Rheumatology, 12, pp. 629-630Raines, M.F., Bhargava, S.K., Rosen, E.S., The blood-retinal barrier in chSidhu, A.B., Verdier-Pinard, D., Fidock, D.A., Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations (2002) Science, 298, pp. 210-213Kublin, J.G., Cortese, J.F., Njunju, E.M., Mukadam, R.A., Wirima, J.J., Kazembe, P.N., Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi (2003) Journal of Infectious Diseases, 187, pp. 1870-1875Mita, T., Kaneko, A., Lum, J.K., Bwijo, B., Takechi, M., Zungu, I.L., Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi (2003) American Journal of Tropical Medicine and Hygiene, 68, pp. 413-415Mwai, L., Ochong, E., Abdirahman, A., Kiara, S.M., Ward, S., Kokwaro, G., Chloroquine resistance before and after its withdrawal in Kenya (2009) Malaria Journal, 8, p. 106Laufer, M.K., Thesing, P.C., Eddington, N.D., Masonga, R., Dzinjalamala, F.K., Takala, S.L., Return of chloroquine antimalarial efficacy in Malawi (2006) The New England Journal of Medicine, 355, pp. 1959-1966Ndiaye, M., Faye, B., Tine, R., Ndiaye, J.L., Lo, A., Abiola, A., Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal (2012) American Journal of Tropical Medicine and Hygiene, 87, pp. 640-645Wurtz, N., Fall, B., Pascual, A., Diawara, S., Sow, K., Baret, E., Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal (2012) Malaria Journal, 11, p. 197Gharbi, M., Flegg, J.A., Hubert, V., Kendjo, E., Metcalf, J.E., Bertaux, L., Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011 (2013) Malaria Journal, 12, p. 35Baird, J.K., Resistance to therapies for infection by Plasmodium vivax (2009) Clinical Microbiology Reviews, 22, pp. 508-534Rieckmann, K.H., Davis, D.R., Hutton, D.C., Plasmodium vivax resistance to chloroquine (1989) Lancet, 2, pp. 1183-1184Castillo, C.M., Osorio, L.E., Palma, G.I., Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia (2002) Memorias do Instituto Oswaldo Cruz, 97, pp. 559-562Ruebush, T.K., Zegarra, J., Cairo, J., Andersen, E.M., Green, M., Pillai, D.R., Chloroquine-resistant Plasmodium vivax malaria in Peru (2003) American Journal of Tropical Medicine and Hygiene, 69, pp. 548-552Soto, J., Toledo, J., Gutierrez, P., Luzz, M., Llinas, N., Cedeno, N., Plasmodium vivax clinically resistant to chloroquine in Colombia (2001) American Journal of Tropical Medicine and Hygiene, 65, pp. 90-93Sumawinata, I.W., Bernadeta Leksana, B., Sutamihardja, A., Purnomo Subianto, B., Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua (2003) American Journal of Tropical Medicine and Hygiene, 68, pp. 416-420Ratcliff, A., Siswantoro, H., Kenangalem, E., Wuwung, M., Brockman, A., Edstein, M.D., Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia (2007) Transactions of the Royal Society of Tropical Medicine and Hygiene, 101, pp. 351-359Tjitra, E., Anstey, N.M., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia (2008) PLoS Medicine, 5, pp. e128Bray, P.G., Hawley, S.R., Mungthin, M., Ward, S.A., Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum (1996) Molecular Pharmacology, 50, pp. 1559-1566Slater, A.F., Swiggard, W.J., Orton, B.R., Flitter, W.D., Goldberg, D.E., Cerami, A., An iron-carboxylate bond links the heme units of malaria pigment (1991) Proceedings of the National Academy of Sciences of the United States of America, 88, pp. 325-329Bray, P.G., Janneh, O., Raynes, K.J., Mungthin, M., Ginsburg, H., Ward, S.A., Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum (1999) Journal of Cell Biology, 145, pp. 363-376Bray, P.G., Mungthin, M., Ridley, R.G., Ward, S.A., Access to hematin: the basis of chloroquine resistance (1998) Molecular Pharmacology, 54, pp. 170-179Pagola, S., Stephens, P.W., Bohle, D.S., Kosar, A.D., Madsen, S.K., The structure of malaria pigment beta-haematin (2000) Nature, 404, pp. 307-310Sullivan, D.J., Gluzman, I.Y., Russell, D.G., Goldberg, D.E., On the molecular mechanism of chloroquine's antimalarial action (1996) Proceedings of the National Academy of Sciences of the United States of America, 93, pp. 11865-11870Sullivan, D.J., Matile, H., Ridley, R.G., Goldberg, D.E., A common mechanism for blockade of heme polymerization by antimalarial quinolines (1998) Journal of Biological Chemistry, 273, pp. 31103-31107Fitch, C.D., Chevli, R., Banyal, H.S., Phillips, G., Pfaller, M.A., Krogstad, D.J., Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex (1982) Antimicrobial Agents and Chemotherapy, 21, pp. 819-822Krogstad, D.J., Schlesinger, P.H., A perspective on antimalarial action: effects of weak bases on Plasmodium falciparum (1986) Biochemical Pharmacology, 35, pp. 547-552Krogstad, D.J., Schlesinger, P.H., Gluzman, I.Y., Antimalarials increase vesicle pH in Plasmodium falciparum (1985) Journal of Cell Biology, 101, pp. 2302-2309Wunsch, S., Sanchez, C.P., Gekle, M., Grosse-Wortmann, L., Wiesner, J., Lanzer, M., Differential stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium falciparum (1998) Journal of Cell Biology, 140, pp. 335-345Sanchez, C.P., Wunsch, S., Lanzer, M., Identification of a chloroquine importer in Plasmodium falciparum. Differences in import kinetics are genetically linked with the chloroquine-resistant phenotype (1997) Journal of Biological Chemistry, 272, pp. 2652-2658Fitch, C.D., Chloroquine resistance in malaria: a deficiency of chloroquine binding (1969) Proceedings of the National Academy of Sciences of the United States of America, 64, pp. 1181-1187Krogstad, D.J., Gluzman, I.Y., Kyle, D.E., Oduola, A.M., Martin, S.K., Milhous, W.K., Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance (1987) Science, 238, pp. 1283-1285Fidock, D.A., Nomura, T., Talley, A.K., Cooper, R.A., Dzekunov, S.M., Ferdig, M.T., Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance (2000) Molecula